Duopharma Biotech Berhad

Kuala Lumpur Stock Exchange 7148.KL

Duopharma Biotech Berhad Debt to Equity Ratio for the year ending December 31, 2023: 0.80

Duopharma Biotech Berhad Debt to Equity Ratio is 0.80 for the year ending December 31, 2023, a 21.26% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Duopharma Biotech Berhad Debt to Equity Ratio for the year ending December 31, 2022 was 0.66, a 1.78% change year over year.
  • Duopharma Biotech Berhad Debt to Equity Ratio for the year ending December 31, 2021 was 0.65, a 37.36% change year over year.
  • Duopharma Biotech Berhad Debt to Equity Ratio for the year ending December 31, 2020 was 0.47, a -6.17% change year over year.
  • Duopharma Biotech Berhad Debt to Equity Ratio for the year ending December 31, 2019 was 0.50, a -0.80% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
Kuala Lumpur Stock Exchange: 7148.KL

Duopharma Biotech Berhad

CEO Mr. Wan Amir-Jeffery Bin Wan Abdul Majid
IPO Date July 19, 2002
Location Malaysia
Headquarters CIMB HUB
Employees 1,650
Sector Health Care
Industries
Description

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.

Similar companies

7106.KL

Supermax Corporation Berhad

USD 0.25

-1.78%

7153.KL

Kossan Rubber Industries Bhd

USD 0.54

-0.45%

7113.KL

Top Glove Corporation Bhd.

USD 0.27

-0.87%

5168.KL

Hartalega Holdings Berhad

USD 0.80

-0.04%

StockViz Staff

January 15, 2025

Any question? Send us an email